<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01648322</url>
  </required_header>
  <id_info>
    <org_study_id>GC-627-02</org_study_id>
    <nct_id>NCT01648322</nct_id>
  </id_info>
  <brief_title>Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy</brief_title>
  <official_title>A Phase II, Randomized, Multi-Centre, Open-Label, Active-Controlled, Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Generon (Shanghai) Corporation Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Generon (Shanghai) Corporation Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized open label dose finding study to evaluate the efficacy and safety of
      F-627 on women with Stage I-IV breast cancer receiving chemotherapy treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, multi-center, dose finding, open label, positive controlled Phase II
      study of the efficacy and safety of once-per-cycle of F-627 compared with Neulasta®
      (pegfilgrastim) in women with breast cancer who are receiving myelotoxic chemotherapy (TC:
      docetaxel + cyclophosphamide or TAC: docetaxel + doxorubicin + cyclophosphamide).

      The primary objective of this study is to evaluate the efficacy and safety of various single
      cycle doses of F-627 as compared with the standard dosing of Neulasta® (pegfilgrastim) in
      breast cancer patients experiencing myelotoxic chemotherapy. Myelotoxicity in this study will
      be defined by the duration of moderate neutropenia; the number of days in which the patient
      has had an absolute neutrophil count (ANC) &lt; 1.0 × 10^9/L during the first cycle of their
      chemotherapy treatment (each chemotherapy cycle is expected to last 21 days). This, by
      definition, includes grade 3 (moderate) and grade 4 (severe) neutropenia. Doses of F-627 to
      be tested for subjects receiving TC chemotherapy are 80 µg/kg/dose, 240 µg/kg/dose, and 320
      µg/kg/dose. For subjects receiving TAC chemotherapy, only 240 µg/kg/dose and 320 µg/kg/dose
      are to be tested.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of Moderate Neurtopenia Post First Chemotherapy Administration</measure>
    <time_frame>The first of 4, 21 Day Chemotherapy Cycles</time_frame>
    <description>Number of days In which the patient has had an absolute neutrophil count (ANC) Level &lt; 2.0 x 10^9/L after first cycle of chemotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration in Days of Grade 3 and Grade 4 Neutropenia for Each of 4 Chemotherapy Cycles.</measure>
    <time_frame>Measured for each of the 4, 21 day chemotherapy cycles.</time_frame>
    <description>Number of days In which the patient has had an ANC &lt; 1.0 × 10^9/L (Grade 3) or ANC &lt; .5 × 10^9/L (Grade 4) post each chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Incidence Rate of Febrile Neutropenia</measure>
    <time_frame>Measured for each of the 4, 21 day chemotherapy cycles.</time_frame>
    <description>The incidence rate of febrile neutropenia for each arm of the study will be recorded for 4 chemotherapy cycles. Each cycle is expected to last 21 Days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Duration in Days of Total Grade 2 Neutropenia</measure>
    <time_frame>Measured for each of the 4, 21 day chemotherapy cycles.</time_frame>
    <description>Number of says in which the patient has had an ANC Level ANC &lt; 1.5 × 109/L) post each chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Time to ANC Recovery Post Nadir</measure>
    <time_frame>Measured for each of the 4, 21 day chemotherapy cycles.</time_frame>
    <description>The time to ANC recovery post nadir for each patient, for each of their chemotherapy cycles will be recorded; recovery for this protocol is defined as achieving an ANC ≥ 2.0 × 10^9/L after the expected ANC nadir (expected nadir is typically 4-6 days post chemotherapy administration). Each chemotherapy cycle is expected to last 21 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Incidence Rates of Grade 2, Grade 3, and Grade 4 Neutropenia for All Chemotherapy Cycles</measure>
    <time_frame>Measured for each of the 4, 21 day chemotherapy cycles.</time_frame>
    <description>The incidence rate of mild, moderate and sever neutropenia for each arm of the study will be recorded for 4 chemotherapy cycles. Each cycle is expected to last 21 Days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Depth of the ANC Nadir for All Chemotherapy Cycles</measure>
    <time_frame>Measured for each of the 4, 21 day chemotherapy cycles</time_frame>
    <description>The depth of ANC nadir for each cycle is defined as the minimal ANC value for a subject in each chemotherapy cycle. The depth of the ANC nadir for each arm of the study will be recorded for 4 chemotherapy cycles.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">232</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Neutropenia</condition>
  <arm_group>
    <arm_group_label>80 µg/kg/dose of F-627</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This dose of F-627 given only to subjects that are to have TC chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>240 µg/kg/dose of F-627</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This dose of F-627 given to subjects receiving TC or TAC chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>320 µg/kg/dose of F-627</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This dose of F-627 given to subjects receiving TC or TAC chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neulasta® (pegfilgrastim)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Given to subjects receiving TC or TAC chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>F-627</intervention_name>
    <description>subcutaneous injection given 1 per chemotherapy.</description>
    <arm_group_label>80 µg/kg/dose of F-627</arm_group_label>
    <arm_group_label>240 µg/kg/dose of F-627</arm_group_label>
    <arm_group_label>320 µg/kg/dose of F-627</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neulasta® (pegfilgrastim)</intervention_name>
    <description>Single dose injection given once per chemotherapy cycle.</description>
    <arm_group_label>Neulasta® (pegfilgrastim)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Show evidence of a signed (personally or by a legally acceptable representative) and
             dated informed consent document indicating that the patient has been informed of all
             pertinent aspects of the trial.

          -  Females ≥ 18 years of age.

          -  Diagnosed with Stage I-IV breast cancer.

          -  Subject is scheduled to undergo 4 cycles of TC or TAC chemotherapy (Taxotere®,
             doxorubicin and cyclophosphamide, 75, 50 and 600 mg/m2, respectively).

          -  ECOG Performance status of ≤ 2.

          -  White Blood Cell count (WBC) ≥ 4.0 × 109/L, hemoglobin ≥ 11.5 g/dL and a platelet
             count ≥ 150 × 109/L.

          -  Demonstrate adequate renal, hepatic function (Liver function tests (ALT, AST, alkaline
             phosphatase and total bilirubin)) should be less than 2.5x upper limits of normal
             (ULN). Serum creatinine should be less than 1.7x ULN.

          -  All subjects must agree to use at least one of the following types of contraception:
             intrauterine device, implantable progesterone device, progesterone intramuscular
             injection, or oral contraceptive, which has been started at least one month prior to
             visit one and will continue for the duration of the trial. The contraceptive patch or
             condom use with spermicide are also acceptable forms of contraception as long as they
             will be used continually throughout the duration of the trial.

        Exclusion Criteria:

          -  Subject is &lt;18 or ≥ 75 years of age.

          -  Disease progression has occurred while receiving a taxane regimen.

          -  Subject has undergone radiation therapy within 4 weeks of enrollment.

          -  Subject has undergone bone marrow or stem-cell transplantation.

          -  Subject has a history of prior malignancy other than breast cancer.

          -  Subjects that have used G-CSF within 6 weeks of the screening period are also excluded

          -  Subject has had chemotherapy within 365 days of screening

          -  Subject has documented congestive heart failure, cardiomyopathy or myocardial
             infarction by clinical diagnosis, ECG test, or any other relevant test.

          -  History of alcohol or drug abuse that would interfere with the ability to be compliant
             with the study procedure.

          -  Unwillingness to participate in the study.

          -  Any underlying medical condition that, in the Investigator's opinion, would make the
             administration of study drug hazardous to the patient or that would obscure the
             interpretation of adverse events.

          -  Receiving other investigational drugs or biologics within 1 month or five half lives
             of enrollment.

          -  Any condition, which can cause splenomegaly.

          -  Chronic constipation or diarrhea, irritable bowel syndrome, inflammatory bowel
             disease.

          -  ALT, AST, alkaline phosphatase &gt; 2.5 upper limit of normal.

          -  Patients with active infection, or known to be infected with chronic active Hepatitis
             B within the last 1 year (unless shown at the time of study entry to be Hepatitis B
             antigen negative), or having any history of Hepatitis C.

          -  Women who are pregnant or breast-feeding.

          -  Patients known to be seropositive for HIV, or who have had an AIDS defining illness or
             a known immunodeficiency disorder.

          -  Patients with a history of tuberculosis or exposure to tuberculosis. Patients that
             have received a prior chest X-ray for suspicion of tuberculosis are also excluded
             unless they have been confirmed to be PPD negative or they had latent tuberculosis
             that has been previously treated.

          -  Subjects with Sickle Cell disease

          -  Subjects with known hypersensitivity to E.coli derived proteins' pegfilgrastim'
             filgrastim, or any other component of the study drug.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Community Hospital of Anderson</name>
      <address>
        <city>Anderson</city>
        <state>Indiana</state>
        <zip>46011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2012</study_first_submitted>
  <study_first_submitted_qc>July 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2012</study_first_posted>
  <results_first_submitted>August 26, 2016</results_first_submitted>
  <results_first_submitted_qc>February 20, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 20, 2018</results_first_posted>
  <last_update_submitted>February 20, 2018</last_update_submitted>
  <last_update_submitted_qc>February 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Taxotere Chemotherapy</keyword>
  <keyword>Neulasta</keyword>
  <keyword>efficacy and safety</keyword>
  <keyword>single cycle doses of F-627</keyword>
  <keyword>pegfilgrastim</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>80 µg/kg/Dose of F-627</title>
          <description>This dose of F-627 given only to subjects that are to have TC chemotherapy.
F-627: subcutaneous injection given 1 per chemotherapy.</description>
        </group>
        <group group_id="P2">
          <title>240 µg/kg/Dose of F-627</title>
          <description>This dose of F-627 given to subjects receiving TC or TAC chemotherapy.
F-627: subcutaneous injection given 1 per chemotherapy.</description>
        </group>
        <group group_id="P3">
          <title>320 µg/kg/Dose of F-627</title>
          <description>This dose of F-627 given to subjects receiving TC or TAC chemotherapy.
F-627: subcutaneous injection given 1 per chemotherapy.</description>
        </group>
        <group group_id="P4">
          <title>Neulasta® (Pegfilgrastim)</title>
          <description>Given to subjects receiving TC or TAC chemotherapy.
Neulasta® (pegfilgrastim): Single dose injection given once per chemotherapy cycle.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="67"/>
                <participants group_id="P3" count="65"/>
                <participants group_id="P4" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="62"/>
                <participants group_id="P3" count="60"/>
                <participants group_id="P4" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>80 µg/kg/Dose of F-627</title>
          <description>This dose of F-627 given only to subjects that are to have TC chemotherapy.
F-627: subcutaneous injection given 1 per chemotherapy.</description>
        </group>
        <group group_id="B2">
          <title>240 µg/kg/Dose of F-627</title>
          <description>This dose of F-627 given to subjects receiving TC or TAC chemotherapy.
F-627: subcutaneous injection given 1 per chemotherapy.</description>
        </group>
        <group group_id="B3">
          <title>320 µg/kg/Dose of F-627</title>
          <description>This dose of F-627 given to subjects receiving TC or TAC chemotherapy.
F-627: subcutaneous injection given 1 per chemotherapy.</description>
        </group>
        <group group_id="B4">
          <title>Neulasta® (Pegfilgrastim)</title>
          <description>Given to subjects receiving TC or TAC chemotherapy.
Neulasta® (pegfilgrastim): Single dose injection given once per chemotherapy cycle.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
            <count group_id="B2" value="67"/>
            <count group_id="B3" value="65"/>
            <count group_id="B4" value="65"/>
            <count group_id="B5" value="232"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.7" spread="10.3"/>
                    <measurement group_id="B2" value="47.9" spread="10.1"/>
                    <measurement group_id="B3" value="48.9" spread="10.3"/>
                    <measurement group_id="B4" value="48.2" spread="10.9"/>
                    <measurement group_id="B5" value="48.4" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="65"/>
                    <measurement group_id="B4" value="65"/>
                    <measurement group_id="B5" value="232"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.28" spread="17.12"/>
                    <measurement group_id="B2" value="70.89" spread="14.44"/>
                    <measurement group_id="B3" value="70.22" spread="12.94"/>
                    <measurement group_id="B4" value="71.28" spread="14.09"/>
                    <measurement group_id="B5" value="71.18" spread="14.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="164.88" spread="5.66"/>
                    <measurement group_id="B2" value="163.58" spread="8.15"/>
                    <measurement group_id="B3" value="162.90" spread="5.66"/>
                    <measurement group_id="B4" value="162.80" spread="6.99"/>
                    <measurement group_id="B5" value="163.37" spread="6.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ECOG status</title>
          <description>The ECOG Scale of Performance Status describes a patient’s level of functioning in terms of their ability to care for themselves, daily activity, and physical ability (walking, working, etc.).
GRADE 0. Fully active
Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature
Ambulatory and capable of all self care but unable to carry out any work activities
A subject's ECOG grade is determined by the study doctor based on the established criteria listed above.
Grade 0 is best. Grade 2 is worse than Grade 1.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Grade 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="41"/>
                    <measurement group_id="B5" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cancer Stage at screen</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Duration of Moderate Neurtopenia Post First Chemotherapy Administration</title>
        <description>Number of days In which the patient has had an absolute neutrophil count (ANC) Level &lt; 2.0 x 10^9/L after first cycle of chemotherapy</description>
        <time_frame>The first of 4, 21 Day Chemotherapy Cycles</time_frame>
        <population>per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>80 µg/kg/Dose of F-627(TC)</title>
            <description>This dose of F-627 given only to subjects that are to have TC chemotherapy.
F-627: subcutaneous injection given 1 per chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>240 µg/kg/Dose of F-627 (TC)</title>
            <description>This dose of F-627 given to subjects receiving TC or TAC chemotherapy.
F-627: subcutaneous injection given 1 per chemotherapy.</description>
          </group>
          <group group_id="O3">
            <title>320 µg/kg/Dose of F-627 (TC)</title>
            <description>This dose of F-627 given to subjects receiving TC or TAC chemotherapy.
F-627: subcutaneous injection given 1 per chemotherapy.</description>
          </group>
          <group group_id="O4">
            <title>Neulasta® (Pegfilgrastim) (TC)</title>
            <description>Neulasta fixed dose of 6mg given to subjects receiving TC or TAC chemotherapy.
Neulasta® (pegfilgrastim): Single dose injection given once per chemotherapy cycle.</description>
          </group>
          <group group_id="O5">
            <title>240 µg/kg/Dose of F-627 (TAC)</title>
            <description>This dose of F-627 given to subjects receiving TAC chemotherapy.
F-627: subcutaneous injection given 1 per chemotherapy.</description>
          </group>
          <group group_id="O6">
            <title>320 µg/kg/Dose of F-627 (TAC)</title>
            <description>This dose of F-627 given to subjects receiving TAC chemotherapy.
F-627: subcutaneous injection given 1 per chemotherapy.</description>
          </group>
          <group group_id="O7">
            <title>Neulasta® (Pegfilgrastim) (TAC)</title>
            <description>Neulasta fixed dose of 6mg given to subjects receiving TAC chemotherapy.
F-627: subcutaneous injection given 1 per chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Moderate Neurtopenia Post First Chemotherapy Administration</title>
          <description>Number of days In which the patient has had an absolute neutrophil count (ANC) Level &lt; 2.0 x 10^9/L after first cycle of chemotherapy</description>
          <population>per protocol population</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="29"/>
                <count group_id="O7" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="1.26"/>
                    <measurement group_id="O2" value="0.6" spread="1.01"/>
                    <measurement group_id="O3" value="0.4" spread="0.75"/>
                    <measurement group_id="O4" value="0.3" spread="0.56"/>
                    <measurement group_id="O5" value="2.1" spread="1.58"/>
                    <measurement group_id="O6" value="2.1" spread="1.46"/>
                    <measurement group_id="O7" value="1.8" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration in Days of Grade 3 and Grade 4 Neutropenia for Each of 4 Chemotherapy Cycles.</title>
        <description>Number of days In which the patient has had an ANC &lt; 1.0 × 10^9/L (Grade 3) or ANC &lt; .5 × 10^9/L (Grade 4) post each chemotherapy</description>
        <time_frame>Measured for each of the 4, 21 day chemotherapy cycles.</time_frame>
        <posting_date>01/2019</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Incidence Rate of Febrile Neutropenia</title>
        <description>The incidence rate of febrile neutropenia for each arm of the study will be recorded for 4 chemotherapy cycles. Each cycle is expected to last 21 Days.</description>
        <time_frame>Measured for each of the 4, 21 day chemotherapy cycles.</time_frame>
        <posting_date>01/2019</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Duration in Days of Total Grade 2 Neutropenia</title>
        <description>Number of says in which the patient has had an ANC Level ANC &lt; 1.5 × 109/L) post each chemotherapy</description>
        <time_frame>Measured for each of the 4, 21 day chemotherapy cycles.</time_frame>
        <posting_date>01/2019</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Time to ANC Recovery Post Nadir</title>
        <description>The time to ANC recovery post nadir for each patient, for each of their chemotherapy cycles will be recorded; recovery for this protocol is defined as achieving an ANC ≥ 2.0 × 10^9/L after the expected ANC nadir (expected nadir is typically 4-6 days post chemotherapy administration). Each chemotherapy cycle is expected to last 21 days.</description>
        <time_frame>Measured for each of the 4, 21 day chemotherapy cycles.</time_frame>
        <posting_date>01/2019</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Incidence Rates of Grade 2, Grade 3, and Grade 4 Neutropenia for All Chemotherapy Cycles</title>
        <description>The incidence rate of mild, moderate and sever neutropenia for each arm of the study will be recorded for 4 chemotherapy cycles. Each cycle is expected to last 21 Days.</description>
        <time_frame>Measured for each of the 4, 21 day chemotherapy cycles.</time_frame>
        <posting_date>01/2019</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Depth of the ANC Nadir for All Chemotherapy Cycles</title>
        <description>The depth of ANC nadir for each cycle is defined as the minimal ANC value for a subject in each chemotherapy cycle. The depth of the ANC nadir for each arm of the study will be recorded for 4 chemotherapy cycles.</description>
        <time_frame>Measured for each of the 4, 21 day chemotherapy cycles</time_frame>
        <posting_date>01/2019</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Subjects were to be followed up 30 days after the last study visit for identification of AEs. Subsequent to the 30 day AE follow-up, subjects who discontinued due to FN were to be followed up for an additional 30 days to identify further FN events or severe neutropenia (defined as ANC &lt;0.5×109/L) with duration &gt;2 days. Any Grade 3 or 4 AEs or SAEs were to be followed up until they had resolved or stabilized.</time_frame>
      <desc>The NCI CTCAE v4.0 grading system was used in AE reporting to provide a standard language to describe toxicities, to facilitate tabulation and analysis of the data, and to facilitate the assessment of the clinical significance of all AEs. AEs were to be recorded and graded 1 to 5 according to the CTCAE grades provided below:
Grade 1 Mild AE Grade 2 Moderate AE Grade 3 Severe and undesirable AE Grade 4 Life-threatening or disabling AE Grade 5 Death</desc>
      <group_list>
        <group group_id="E1">
          <title>80 µg/kg/Dose of F-627</title>
          <description>This dose of F-627 given only to subjects that are to have TC chemotherapy.
F-627: subcutaneous injection given 1 per chemotherapy.</description>
        </group>
        <group group_id="E2">
          <title>240 µg/kg/Dose of F-627</title>
          <description>This dose of F-627 given to subjects receiving TC or TAC chemotherapy.
F-627: subcutaneous injection given 1 per chemotherapy.</description>
        </group>
        <group group_id="E3">
          <title>320 µg/kg/Dose of F-627</title>
          <description>This dose of F-627 given to subjects receiving TC or TAC chemotherapy.
F-627: subcutaneous injection given 1 per chemotherapy.</description>
        </group>
        <group group_id="E4">
          <title>Neulasta® (Pegfilgrastim)</title>
          <description>Neulasta fixed dose of 6mg given to subjects receiving TC or TAC chemotherapy.
Neulasta® (pegfilgrastim): Single dose injection given once per chemotherapy cycle.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>NCI CTCAE v4.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis Toxic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>NCI CTCAE v4.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="59" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="52" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Generon (shanghai) corporation</organization>
      <phone>8621-61760866</phone>
      <email>tangt@generonbiomed.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

